Intravenous Ferric Carboxymaltose versus Oral Ferrous Sulphate for the Treatment of Postpartum Anemia in Nigerian women (IVON-PP): a randomised controlled trial.
Women Randomized
FCM Group (Ferrous Carboxymaltose)
as at Friday, 21th June 2024.
FS Group (Ferrous Sulphate)
Postpartum anaemia which is often caused by iron deficiency anaemia alone or in combination with blood loss at delivery, occurs at an estimated prevalence of 50 – 80% in low middle income country. It poses adverse consequences on the mother and these negative impacts can affect her ability to care for her newborn.
Our aim is to determine the clinical effectiveness, tolerability, safety, cost-effectiveness, implementation climate and outcomes of using intravenous ferric carboxymaltose (intervention) versus oral ferrous sulphate (control) for treating iron deficiency anemia in postpartum women.
